Compositions and methods for the treatment or prevention of human immunodeficiency virus infection
Inventors
King, Thomas H. • Apelian, David
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-10849971-B2
Publication Date
2020-12-01
Expiration Date
Abstract
Disclosed are yeast-based immunotherapeutic compositions, human immunodeficiency virus (HIV) antigens, and fusion proteins for the treatment and/or prevention of HIV infection and symptoms thereof, as well as methods of using the yeast-based immunotherapeutic compositions, HIV antigens, and fusion proteins for the prophylactic and/or therapeutic treatment of HIV and/or symptoms thereof.
Core Innovation
The invention provides a yeast-based immunotherapeutic composition comprising a yeast vehicle and a fusion protein comprising HIV antigens. The HIV antigens comprise an amino acid sequence that is at least 95% identical to SEQ ID NO:9, including HIV Gag antigen components, and the fusion protein is associated with HIV antigen content suitable for eliciting HIV-specific T cell responses.
A further aspect specifies immunotherapeutic compositions in which whole, inactivated yeast is used as the yeast vehicle and the HIV fusion protein comprises the amino acid sequence of SEQ ID NO:9. The fusion protein is under the control of the promoter CUP1 and is expressed by the yeast, and the resulting composition elicits an HIV-specific T cell response.
Additional embodiments include a yeast-expressed HIV Gag protein that forms very large particles (VLPs) when expressed by the yeast, with the HIV antigen comprising SEQ ID NO:9. Another embodiment covers HIV Gag antigens comprising Sector 3 epitopes and/or Sector 1 epitopes, with the HIV antigen comprising SEQ ID NO:9.
Claims Coverage
The independent claims cover yeast-based immunotherapeutic compositions and HIV fusion proteins centered on SEQ ID NO:9. Across the claims, the inventive features include the yeast vehicle form, whole inactivated yeast, CUP1 promoter control, yeast expression, HIV-specific T cell response, VLP formation, and Sector 3 and/or Sector 1 epitopes.
Yeast vehicle with HIV fusion protein sequence identity to SEQ ID NO:9
An immunotherapeutic composition comprising a yeast vehicle and a fusion protein comprising HIV antigens, wherein the HIV antigens comprise an amino acid sequence that is at least 95% identical to SEQ ID NO:9.
Whole, inactivated yeast with CUP1-controlled SEQ ID NO:9 HIV fusion protein expressed by the yeast
An immunotherapeutic composition comprising whole, inactivated yeast; an HIV fusion protein comprising the amino acid sequence of SEQ ID NO:9, wherein the fusion protein is under the control of the promoter CUP1; wherein the HIV fusion protein is expressed by the yeast; and wherein the composition elicits an HIV-specific T cell response.
Yeast-expressed HIV Gag antigen forming very large particles (VLPs) with SEQ ID NO:9
An immunotherapeutic composition comprising a yeast and an HIV antigen expressed by the yeast and comprising an HIV Gag protein, wherein the HIV Gag protein forms very large particles (VLPs) when expressed by the yeast, wherein the HIV antigen comprises SEQ ID NO:9.
Yeast vehicle with HIV Gag antigen containing Sector 3 and/or Sector 1 epitopes defined by SEQ ID NO:9
An immunotherapeutic composition comprising a yeast vehicle and at least one HIV antigen that comprises an HIV Gag antigen comprising Sector 3 epitopes and/or Sector 1 epitopes, wherein the HIV antigen comprises SEQ ID NO:9.
Fusion protein defined by at-least-95% identity to SEQ ID NO:9
A fusion protein comprising HIV antigens, wherein the fusion protein comprises an amino acid sequence that is at least 95% identical to an amino acid sequence of SEQ ID NO:9.
Claim coverage centers on yeast-based immunotherapeutic compositions and HIV fusion proteins defined by sequence constraints relative to SEQ ID NO:9. Independent claims further specify whole, inactivated yeast; CUP1 promoter control and yeast expression; HIV Gag VLP formation; and inclusion of Sector 3 and/or Sector 1 epitopes.
Stated Advantages
Elicits an HIV-specific T cell response.
Reduces HIV infection and/or at least one HIV-related symptom.
Documented Applications
Treatment of HIV infection or HIV-related symptoms by administering the immunotherapeutic composition to an HIV-infected subject to reduce HIV infection and/or HIV-related symptoms.
Eliciting HIV-specific T cell response using a yeast-based immunotherapeutic composition with a CUP1-controlled yeast-expressed HIV fusion protein.
Interested in licensing this patent?